Spotlight
Video

GRACEcastUC-017_Lung_A promising option for people with the most common lung cancer mutation?

cancergrace has 795 videos Subscribe Here

Loading........
Description: http://cancerGRACE.org/...

Dr. Jack West reviews the encouraging results with selumetinib, a MEK inhibitor, in combination with chemotherapy for patients with advanced NSCLC and a KRAS mutation, the most common molecular marker seen in lung cancer.
Shared By : cancergrace
Posted on : 05/01/13
Added : 4 years ago
Category : Other